Astrazeneca Plc (AZN)

TheFly reported on June 15 that AZN announced that its supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab) was accepted and granted Priority Review by the U.S.

The anti-obesity drug (AOM) market in the United States is rapidly changing structurally.

On June 11, Emily Roland, the Co-Chief Investment Strategist at Manulife John Hancock Investment Management, joined 'Squawk Box' on CNBC to discuss where investors can find opportunity right now.

In this article, we will look at the stocks Jim Cramer discussed on Mad Money, along with the recent sell-off in the market.

AstraZeneca PLC (NYSE:AZN) is one of the best stocks to buy now for long term growth. AstraZeneca PLC (NYSE:AZN) reported on May 29 that the global CARES Phase III clinical programme showed that treatment...

On May 29, Andrew Slimmon, Senior Portfolio Manager at Morgan Stanley, appeared on CNBC’s 'Closing Bell' to talk about equity markets, whether investors should keep riding the tech winning streak, and...

TheFly reported on May 6 that CDT Equity announced that AZD5904, a selective inhibitor of human myeloperoxidase originally licensed from AstraZeneca PLC (NYSE:AZN), has entered the Patent Cooperation ...

On April 30, Bloomberg reported that Steve Cohen resigned as president of Point72 Asset Management, and Harry Schwefel was appointed co-CIO.

Pharmaceutical firms have always had a special place in the healthcare market because they provide stability and expansion.